Septerna (NASDAQ:SEPN) Announces Quarterly Earnings Results

Septerna (NASDAQ:SEPN) released its quarterly earnings results on Monday. The company reported ($0.19) earnings per share for the quarter, FiscalAI reports. Septerna had a negative net margin of 106.37% and a negative return on equity of 15.85%.

Septerna Stock Down 1.3%

Shares of SEPN traded down $0.30 during mid-day trading on Monday, hitting $23.57. 132,725 shares of the company’s stock were exchanged, compared to its average volume of 307,262. Septerna has a 52 week low of $6.44 and a 52 week high of $32.63. The stock’s 50-day simple moving average is $25.51 and its 200-day simple moving average is $25.40. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -21.23 and a beta of 2.21.

Analyst Ratings Changes

SEPN has been the topic of several research analyst reports. Wells Fargo & Company increased their price target on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Wall Street Zen cut shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. JPMorgan Chase & Co. raised their target price on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Septerna in a report on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.13.

Insider Activity at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $4,240,247.06. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the sale, the insider owned 793 shares in the company, valued at $22,283.30. This represents a 98.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 78,453 shares of company stock worth $2,192,969 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Septerna

Several large investors have recently made changes to their positions in SEPN. Group One Trading LLC boosted its position in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after acquiring an additional 8,955 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Septerna during the 4th quarter worth approximately $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna during the 4th quarter worth approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna in the fourth quarter valued at approximately $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.